

NEW:
CE approved

Treatment of addiction*

Psychoactive Substance
Use Disorder (PSUD)

- 13-minute TMS treatment sessions
- First CE approval for PSUD
- Outpatient procedure
- Non-drug treatment, no anesthesia
- May be combined with other therapies (such as psychotherapy)



MagVenture TMS Therapy
Stimulating mental health.

Further details


MagVenture's CE approval is based on a pilot study¹ as well as the largest naturalistic study with the longest follow-up period available so far². These studies have contributed to the world's first CE approval for TMS therapy for addiction (PSUD)².

“

The experimental group treated with TMS showed a significant reduction in cravings, relapses, and dropouts compared to a control group.

*Luigi Gallimberti
Psychiatrist, toxicologist and
professor, The University of
Padua*

The efficacy of TMS



Graphics by MagVenture, based on:

¹Terraneo et al., 2016, European Neuropsychopharmacology: Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study.

^{1a}Madeo et al., 2020: Long-Term Outcome of Repetitive Transcranial Magnetic Stimulation in a Large Cohort of Patients With Cocaine-Use Disorder: An Observational Study.

TMS for Addiction

MagVenture TMS Therapy[®] is an advanced neuromodulation technology that uses magnetic pulses to stimulate the affected areas in the brain.

MagVenture TMS Therapy[®] is intended to be used as a treatment of psychoactive stimulant use disorder (PSUD) in adult patients. Most common side effects are headache and nausea.

The total treatment time is 13 weeks for a total of 34 treatment sessions:

- Two treatments per day for five days, followed by:
- 2 treatments per day one day weekly for 12 weeks.
- Additional TMS sessions may be applied, for instance, in case of a relapse or the risk of relapse.



Need more information?

MagVenture offers solutions ranging from the simplest systems to high-performance setups tailored for high patient throughput and upgradable for possible future indications. MagVenture products are available worldwide through direct sales subsidiaries in Germany, the UK, the US, and Brazil and represented in over 55 countries through carefully selected global partners.

To find out more, please contact MagVenture directly at info@magventure.com or simply visit www.magventure.com

CE Approval

*MagVenture TMS Therapy[®] is indicated as “treatment of psychoactive substance use disorder (PSUD) in adult patients.”

MagVenture TMS Therapy
Stimulating mental health.